September 3, 2008
Menlo Park, CA—iScience Interventional has received expanded 510(k) clearance from the FDA to allow ophthalmic surgeons to use its microcatheters to enlarge outflow passages to reduce IOP in the treatment of primary open-angle glaucoma (POAG).
 |
September 3, 2008
San Francisco—The American Academy of Ophthalmology (AAO) has announced the slate of candidates for board positions that have terms beginning Jan. 1.
|
September 3, 2008
South San Francisco, CA—A special committee of the Genentech Board of Directors has unanimously rejected a proposal by Roche under which Roche would have acquired the shares of Genentech it did not own for $89 per share.
|
September 3, 2008
Lexington, SC, and Colorado Springs, CO—Biosyntrx Corp. is partnering with Wellosophy Corp. to include a professional-strength version of a proprietary hydrogel gastric bulking technology (Swell) into Biosyntrx’s new mealtime portion-control product (Avantrx).
|
September 3, 2008
East Hanover, NJ—Novartis Pharmaceuticals Corp. has launched the Patient Assistance Now Web site and telephone service to integrate company programs and other resources to help uninsured Americans pay for their Novartis medicines and find health-care information.
|
September 3, 2008
Mountain View, CA—Iridex Corp. has received 510(k) clearance from the FDA for a family of laser systems (IQ 532, IQ 577, IQ 630-670, and IQ 810) and their associated delivery devices to deliver laser energy in three different modes (CW-Pulse, MicroPulse, and LongPulse).
|
August 1, 2008
San Francisco—The American Academy of Ophthalmology (AAO) has accepted planned retirements of two of its senior staff leaders: H. Dunbar Hoskins Jr., MD, executive vice president and chief executive officer (CEO), and David J. Noonan, deputy executive vice president and chief operations officer (COO), according to a prepared statement issued by the AAO.
|
August 1, 2008
South San Francisco—Genentech has formed a special committee of its board of directors to assess the proposal from Roche to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $89 in cash per share.
|
| 
Practice Tools
